BDTX NASDAQ
Black Diamond Therapeutics, Inc.
1W: +0.5%
1M: -11.7%
3M: -4.1%
YTD: -24.1%
1Y: -49.2%
3Y: -34.4%
5Y: -79.7%
$1.89
+0.01 (+0.53%)
Weekly Expected Move ±5.0%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (40)
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock Has Consensus Target Price of $10.25
Black Diamond Therapeutics, Inc. $BDTX Shares Newly Acquired by Bank of America Corp DE
BlackRock Inc. Acquires New Holdings in Black Diamond Therapeutics, Inc. $BDTX
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
What's Going On With Black Diamond Therapeutics Stock Tuesday?
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
12 Health Care Stocks Moving In Friday's Intraday Session
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Black Diamond Therapeutics GAAP EPS of -$0.16 beats by $0.02
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of “Moderate Buy” from Analysts
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026
Black Diamond Stock: Weighing Catalysts vs. Concentration
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
What Makes Black Diamond (BDTX) a New Strong Buy Stock
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout